Comment: Barbiturates may well maximize adverse effects, such as respiratory melancholy, made by harmful doses of TCAs. With therapeutic doses of TCAs, barbiturates enhance metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the extent or influence of theophylline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will decrease the extent or outcome of imatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unidentified.
pentobarbital will lower the extent or result of aripiprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will decrease the extent or impact of alosetron by impacting hepatic enzyme CYP2C9/10 metabolism. Insignificant/Importance Not known.
pentobarbital will reduce the extent or result of losartan by affecting hepatic enzyme CYP2C9/ten metabolism. Minor/Importance Not known.
pentobarbital will lower the extent or outcome of fostemsavir by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
fentanyl intranasal and pentobarbital both maximize sedation. Prevent or Use Alternate Drug. Restrict use to people for whom alternative treatment method alternatives are inadequate
Reserve concomitant prescribing of these drugs in individuals for whom other treatment method selections are inadequate. Limit dosages and durations for the minimum click here expected. Check intently for indications of respiratory despair and sedation.
Remark: Barbiturates may possibly boost adverse effects, which includes respiratory depression, made by harmful doses of TCAs. With therapeutic doses of TCAs, barbiturates enhance metabolism and decrease blood concentrations of TCAs.
pentobarbital decreases levels of toremifene by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. CYP3A4 inducers improve amount of toremifene metabolism, lowering the continual-state focus in serum.
Prevent; coadministration with CYP3A inducers may perhaps bring about decreased plasma concentrations of elvitegravir and/or a concomitantly administered protease inhibitor and lead to loss of therapeutic impact and to achievable resistance
Drugs that have step therapy affiliated with Just about every prescription. This restriction normally requires that selected standards be met previous to approval with the prescription.
pentobarbital will lower the level or influence of tofacitinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lack of, or lowered response to tofacitinib may perhaps arise when coadministered with potent CYP3A4 inducers